<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 17, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H34778573"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The goals of antiretroviral therapy (ART) are to reduce HIV-related morbidity and mortality (from both infectious and noninfectious causes) and to prevent transmission of HIV to others. For most treatment-naïve patients, ART regimens contains two different nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent from a different class. </p><p>This topic will address the approach to choosing an initial ART regimen for treatment-naïve patients with HIV-1 who have comorbid conditions that impact regimen selection, which represent only a small fraction of those starting ART. The general approach to initial regimen selection and other topics relevant to treatment of individuals with HIV include: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16252.html" rel="external">"Treatment of HIV-2 infection"</a>.)</p><p></p><p class="headingAnchor" id="H3609591034"><span class="h1">ANTIRETROVIRAL AGENTS</span><span class="headingEndMark"> — </span>There are more than 25 antiretroviral medications from six major classes currently available for the treatment of patients with HIV  (<a class="graphic graphic_table graphicRef60927" href="/z/d/graphic/60927.html" rel="external">table 1</a>). The most commonly used antiretroviral agents for treatment-naïve patients include nucleoside reverse transcriptase inhibitors (NRTIs), integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). These agents are discussed in detail in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Antiretroviral agents'</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p class="headingAnchor" id="H1543248566"><span class="h1">CONSIDERATIONS PRIOR TO INITIATING ANTIRETROVIRAL THERAPY</span><span class="headingEndMark"> — </span>To optimize individual regimens, we evaluate the treatment-naïve patient for the presence or absence of certain conditions, including renal insufficiency, chronic hepatitis B virus infection, heart disease, pregnancy status, and, if <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> is being considered, the HLA-B*5701 allele. Abacavir is <strong>contraindicated</strong> if the patient is positive for the HLA-B*5701 allele since persons who test positive for HLA-B*5701 are at high risk for developing an abacavir hypersensitivity reaction. (See  <a class="medical medical_review" href="/z/d/html/3779.html" rel="external">"Abacavir hypersensitivity reaction"</a>.)</p><p>Baseline drug resistance testing should also be performed to detect the presence and/or characteristics of a drug-resistant virus. This testing should include reverse transcriptase (nucleoside and non-nucleoside reverse transcriptase) and protease inhibitor resistance; resistance testing for integrase strand transfer inhibitors (INSTIs) is not required unless the source patient is known to have INSTI treatment failure or resistance.</p><p>More detailed discussions of the pretreatment evaluation in patients with HIV are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Considerations prior to initiating treatment'</a>.) </p><p class="headingAnchor" id="H2530681254"><span class="h1">WHEN TO INITIATE ANTIRETROVIRAL THERAPY</span><span class="headingEndMark"> — </span>Antiretroviral therapy (ART) should be offered to all persons with HIV, including asymptomatic individuals, regardless of their immune status [<a href="#rid1">1,2</a>]. The only individuals in whom the benefits of ART are not proven are the small proportion of untreated patients with preserved CD4 cell counts and undetectable HIV RNA (sometimes referred to as HIV controllers). (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a>.)</p><p>For many individuals, we initiate ART soon after their initial diagnosis. Initiating therapy at the initial visit can improve virologic outcomes and retention in care. However, there may be special considerations for patients with certain opportunistic infections (eg, tuberculosis, cryptococcal meningitis) or comorbid conditions. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV", section on 'Timing of treatment'</a>.)</p><p class="headingAnchor" id="H3762318367"><span class="h1">APPROACH TO REGIMEN SELECTION</span></p><p class="headingAnchor" id="H543483080"><span class="h2">General approach</span><span class="headingEndMark"> — </span>For most treatment-naïve patients, we suggest an integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) regimen. We typically administer <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> or <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Approach for most patients'</a>.) </p><p>However, certain patients will have concurrent conditions that impact the choice of regimen. Although many patients with comorbid conditions can still use one of the preferred regimens described above, some may benefit from a regimen that avoids tenofovir (eg, <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a>) or uses a non-nucleoside reverse transcriptase inhibitor (NNRTI) instead of an INSTI  (<a class="graphic graphic_table graphicRef130162" href="/z/d/graphic/130162.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef130164" href="/z/d/graphic/130164.html" rel="external">table 3</a>). If more than one comorbid condition is present, the clinician should review the options for each relevant scenario and select the most appropriate combination. </p><p>In persons who are of childbearing potential or are pregnant, physicians must carefully consider the risks and benefits of the different regimens and share these considerations with the patient. Detailed discussions of the safety of antiretroviral medications in these populations are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">"HIV and women", section on 'Individuals of childbearing potential'</a> and  <a class="medical medical_review" href="/z/d/html/3778.html" rel="external">"Safety and dosing of antiretroviral medications in pregnancy", section on 'Integrase inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings", section on 'ART selection and management'</a> and  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a>.)<strong> </strong></p><p class="headingAnchor" id="H4271022128"><span class="h2">Hepatitis B virus coinfection</span><span class="headingEndMark"> — </span>We make all efforts to administer a tenofovir-containing ART regimen to patients who have chronic hepatitis B virus (HBV) infection. <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">Tenofovir disoproxil fumarate</a> (TDF) and <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF) are both effective in suppressing HBV replication and are also included in the preferred HIV ART regimens  (<a class="graphic graphic_table graphicRef130162" href="/z/d/graphic/130162.html" rel="external">table 2</a>). </p><p>HIV regimens that use <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> or <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> without tenofovir should be <strong>avoided</strong>. These include regimens that use <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">abacavir-lamivudine</a> as the nucleoside combination or a two-drug regimen such as <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a>. Although lamivudine has activity against HBV, lamivudine monotherapy is associated with the rapid emergence of lamivudine-resistant HBV due to mutations within the YMDD motif of HBV reverse transcriptase. </p><p>A detailed discussion of the management of individuals with HIV/HBV coinfection is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a>.)</p><p class="headingAnchor" id="H525142533"><span class="h2">Reduced kidney function</span><span class="headingEndMark"> — </span>The approach to treatment in patients with reduced kidney function depends upon the degree of renal insufficiency.</p><p class="headingAnchor" id="H1987357817"><span class="h3">Agents to avoid</span><span class="headingEndMark"> — </span>For patients with reduced kidney function (estimated glomerular filtration rate [eGFR] &lt;60 min/mL/1.73 m<sup>2</sup>), we avoid TDF, which is associated with proximal tubular dysfunction. However, TAF, a different formulation of tenofovir, can be used in patients with moderately reduced kidney function (eGFR ≥30 min/mL/1.73 m<sup>2</sup>). (See <a class="local">'Moderately reduced kidney function'</a> below.) </p><p>The protease inhibitor (PI) <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> has also been associated with acute and chronic kidney disease and should generally be avoided in patients with reduced kidney function. </p><p>Addition information on nephrotoxicity associated with antiretroviral medications is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p class="headingAnchor" id="H223183738"><span class="h3">Moderately reduced kidney function</span><span class="headingEndMark"> — </span>In patients with an eGFR ≥30 mL/min/1.73 m<sup>2</sup> but &lt;60 mL/min/1.73 m<sup>2</sup>, several treatment options exist. These include one of the preferred three-drug regimens, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a>–<a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> or <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>, as well as the two-drug combination <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a>  (<a class="graphic graphic_table graphicRef130162" href="/z/d/graphic/130162.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef130164" href="/z/d/graphic/130164.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>A TAF-containing regimen should be used for those with chronic hepatitis B infection, those with a viral load &gt;500,000 copies/mL, and most patients with transmitted drug resistance or a CD4 count ≤200 cells/microL. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below and <a class="local">'Hepatitis B virus coinfection'</a> above and  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Patients with transmitted drug resistance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For others, we use a shared decision-making approach to determine if a TAF-containing regimen or <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> should be used. We discuss how using dolutegravir-lamivudine could reduce the risk that even TAF could contribute to potential nephrotoxicity. However, there are fewer long-term data with the use of this regimen, and unlike one of the preferred three-drug regimens, dolutegravir-lamivudine cannot be initiated until the results of the initial evaluation have returned. Additional information on the use of dolutegravir-lamivudine is found below. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below.)</p><p></p><p class="headingAnchor" id="H3457588046"><span class="h3">Severely reduced kidney function</span></p><p class="headingAnchor" id="H2553716451"><span class="h4">Patients on hemodialysis</span><span class="headingEndMark"> — </span>There is limited published experience to guide decisions regarding the preferred regimen for treatment-naïve patients on chronic hemodialysis. Studies evaluating antiretroviral agents in patients on hemodialysis have primarily been in virologically suppressed patients [<a href="#rid3">3-5</a>]. In general, we prefer <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>, since it can be administered as a single tablet once daily. <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">Dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> is also an option and does not require dose adjustment [<a href="#rid1">1</a>]. If TAF is not available, renally dosed <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> can also be used with dolutegravir, although it has not been studied in this population. Special considerations when using dolutegravir plus lamivudine are discussed below. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below.)</p><p class="headingAnchor" id="H3534131476"><span class="h4">Patients not on dialysis</span><span class="headingEndMark"> — </span>In patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup> who are <strong>not</strong> on dialysis, both TAF and TDF should generally be avoided; although TAF has less nephrotoxicity compared with TDF, there are only limited data evaluating the safety of TAF in patients with severely reduced kidney function. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimen</strong> – When choosing a regimen for patients with severely reduced kidney function not on dialysis, we suggest the combination <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> if they meet <strong>all</strong> of the criteria described below. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below.)</p><p></p><p class="bulletIndent1">When using <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> in patients with severely reduced kidney function, the single coformulated tablet should not be used since the dose of lamivudine must be reduced. Thus, the regimen must be administered as two tablets once daily. Additional information on renal dosing is found in the Lexicomp drug information topics within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong> – Some patients cannot take <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> because they do not meet the criteria described below. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below.) </p><p></p><p class="bulletIndent1">Such patients should be managed in conjunction with an expert in HIV care, since the approach must be individualized. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with chronic hepatitis B coinfection, the benefits of using TAF at a lower eGFR may outweigh the potential risk of toxicity. (See  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV", section on 'Tenofovir in patients with reduced kidney function'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with high viral loads, the combination of <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> plus <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> may be reasonable for those who are HLA-B*5701 negative and are without cardiovascular disease. If this regimen is used, the single-pill coformulated tablet should not be administered, as the dose of lamivudine needs to be reduced. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with nucleoside reverse transcriptase inhibitor (NRTI) resistance, the combination of <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus boosted <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a> may be reasonable. Although this specific regimen has not been studied, in a randomized trial of 805 treatment-naïve individuals, darunavir (800 mg) boosted with <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> (100 mg) plus <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> (400 mg twice daily) was noninferior to an established drug combination of ritonavir-boosted darunavir plus <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> after 96 weeks of treatment [<a href="#rid6">6</a>]. We would expect similar or better results when dolutegravir is used rather than raltegravir, since the former has a higher barrier to resistance. </p><p></p><p class="headingAnchor" id="H1594753438"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>For patients who have a history of (or are at high risk for) heart disease, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> or <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a> can be used. If there are contraindications to tenofovir, the two-drug combination <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> is also an option, assuming there are no contraindications, as described below. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below.)</p><p>We avoid <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> in such patients. Although data are conflicting, several studies have found that abacavir can increase the risk of cardiovascular disease [<a href="#rid7">7-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV", section on 'Abacavir'</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Abacavir'</a>.)</p><p>Additional considerations for regimen selection in patients with cardiovascular disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>Impact of ART on lipids – Data from clinical trials show that TAF lowers lipids less than TDF [<a href="#rid12">12,13</a>]; however, the clinical significance of this is unclear. Furthermore, it is unknown whether the lipid-lowering effect of TDF improves clinical outcomes. The INSTIs bictegravir, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>, and <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> have a largely neutral effect on cholesterol and triglycerides compared with <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a> and PIs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an INSTI cannot not be used – If an INSTI is not appropriate (eg, because of drug interactions), <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">rilpivirine</a> can be used as the third agent for patients with a CD4 ≥200 cells/microL and a viral load &lt;100,000 copies/mL, since rilpivirine is also associated with minimal changes in lipids. However, rilpivirine should be avoided, if possible, in patients at risk for torsades de pointes. Another potential option is <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">doravirine</a>, though there is less experience with this NNRTI. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a PI is used<strong> </strong>– If a PI is used in patients at high cardiovascular risk, we prefer to use <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> over other boosted PIs. With the exception of atazanavir, all of the ritonavir-boosted PIs are associated with an increased risk of cardiovascular disease independent of their lipid effects [<a href="#rid14">14</a>]. Furthermore, atazanavir is associated with a decreased risk of myocardial infarction compared with other antiretroviral agents [<a href="#rid15">15</a>] and was shown in a prospective randomized trial to reduce carotid intima media thickness progression more than either <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> or <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a> [<a href="#rid16">16</a>].</p><p></p><p>More detailed discussions of antiretroviral agents and their role in cardiovascular disease are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p class="headingAnchor" id="H3294081890"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>For most patients with osteoporosis, we use a TAF-containing regimen (<a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> or <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>), since the use of TDF, but not TAF, is associated with bone loss [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV"</a>.)</p><p>However, some patients may prefer to avoid even TAF. For such patients, <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> is a reasonable choice, assuming there are no contraindications, as described below. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> below.)</p><p class="headingAnchor" id="H868111430"><span class="h2">Patients with opportunistic infections</span><span class="headingEndMark"> — </span>For patients with HIV who present with opportunistic infections, regimen selection should take into account potential drug interactions. Information on drug interactions can be found in the <a class="external" href="/drug-interactions">Lexicomp drug interaction</a> program within UpToDate and within separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.) </p><p>The treatment of active or latent tuberculosis is one example in which drug interactions may impact the ART regimen, since there are important drug interactions that can be seen with rifamycins and many of the antiretroviral agents used to treat HIV:</p><p class="bulletIndent1"><span class="glyph">●</span>Regimens that contain a boosting agent (eg, <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a> or <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>), PIs, bictegravir, <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">rilpivirine</a>, and <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">doravirine</a> should <strong>not</strong> be used with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Agents such as <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> and <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> require dose adjustment if used with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of TAF plus a rifamycin should be avoided, if possible. Rifamycins appear to reduce TAF levels, although the clinical significance of the interaction with TAF is unclear since intracellular concentrations of tenofovir diphosphate (the active agent) were still 82 percent higher on average than those achieved by standard-dose TDF [<a href="#rid18">18</a>]. </p><p></p><p>For patients who are being treated with a rifampin-containing regimen, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> can be administered with <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> assuming there are no suspected or documented INSTI-associated resistance mutations; however, dolutegravir should be administered as 50 mg twice daily. Other ART options include <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> (800 mg twice daily) with tenofovir disoproxil fumarate-emtricitabine, or <a class="drug drug_general" data-topicid="8858" href="/z/d/drug information/8858.html" rel="external">efavirenz-emtricitabine-tenofovir disoproxil fumarate</a>. <a class="drug drug_general" data-topicid="9010" href="/z/d/drug information/9010.html" rel="external">Abacavir-lamivudine</a> plus dolutegravir (50 mg twice daily) is another option, assuming the patient is HLA-B*5701 negative and the patient does not have hepatitis B virus or cardiovascular disease. After completing treatment for active or latent TB, these regimens can be switched to one of the preferred ART regimens. (See  <a class="medical medical_review" href="/z/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"</a>.)</p><p>Two-drug ART regimens (eg, <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a>, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus boosted <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a>) should <strong>not</strong> be used in patients who are being treated with a rifamycin. </p><p class="bulletIndent1">More detailed discussions of the treatment of active and latent tuberculosis in patients with HIV are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"</a>.)</p><p></p><p class="headingAnchor" id="H803043157"><span class="h1">CONSIDERATIONS WHEN USING DOLUTEGRAVIR-LAMIVUDINE</span><span class="headingEndMark"> — </span>The two-drug regimen <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> may be well suited for patients initiating antiretroviral therapy (ART) with certain comorbid conditions (eg, reduced kidney function, osteoporosis). In clinical trials, this regimen was found to have similar efficacy to <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> in treatment-naïve patients [<a href="#rid19">19</a>]. </p><p>If <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> is being considered, <strong>all</strong> of the following criteria must be met:</p><p class="bulletIndent1"><span class="glyph">●</span>The HIV viral load must be less than 500,000 copies/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There must be no evidence of transmitted resistance to nucleoside reverse transcriptase inhibitors (NRTIs) or integrase strand transfer inhibitors (INSTIs; if INSTI resistance testing was obtained as part of the initial evaluation). (See <a class="local">'Considerations prior to initiating antiretroviral therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient must have no evidence of chronic HBV infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient must not be taking any concurrent medications that would significantly reduce the levels of either antiretroviral agent (eg, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> reduces <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> levels).</p><p></p><p class="bulletIndent1">In addition, the patient should ideally have a CD4 count &gt;200 cells/microL [<a href="#rid2">2</a>]. A low CD4 count is not a contraindication to using this regimen, but we generally avoid <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> in such patients if there are other good treatment options. Few patients with advanced immunosuppression have been treated with dolutegravir-lamivudine, and in the comparative trial comparing dolutegravir-lamivudine with <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="8527" href="/z/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a>, those who had a low CD4 count were less likely to achieve a viral load &lt;50 copies at week 48, although the lower results were mostly due to study dropout, not virologic failure [<a href="#rid19">19</a>]. A detailed discussion of the data supporting the use of this regimen is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Use of two-drug regimens in select patients'</a>.)</p><p></p><p class="headingAnchor" id="H2614857945"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111624.html" rel="external">"Society guideline links: HIV treatment in nonpregnant adults and adolescents"</a>.)</p><p class="headingAnchor" id="H815377123"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16165.html" rel="external">"Patient education: Starting treatment for HIV (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15448.html" rel="external">"Patient education: HIV/AIDS (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3693.html" rel="external">"Patient education: Initial treatment of HIV (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3696.html" rel="external">"Patient education: Tips for taking HIV medications by mouth (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/3697.html" rel="external">"Patient education: Testing for HIV (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H511953068"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The management of HIV involves treatment with combination antiretroviral therapy (ART). The use of these multidrug regimens substantially reduces progression to AIDS, opportunistic infections, hospitalizations, and death. They also prevent transmission of HIV to others. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ART should be offered to all persons with HIV, including asymptomatic individuals, regardless of their immune status. For many individuals, we initiate ART soon after their initial diagnosis, even before the results of baseline testing have returned. (See <a class="local">'When to initiate antiretroviral therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most treatment-naïve patients, we suggest an ART regimen of <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> or <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>  (<a class="graphic graphic_table graphicRef130162" href="/z/d/graphic/130162.html" rel="external">table 2</a>). However, there are special considerations for patients with certain comorbid conditions (eg, chronic hepatitis B virus infection, reduced kidney function, cardiovascular disease, osteoporosis, opportunistic infections)  (<a class="graphic graphic_table graphicRef130164" href="/z/d/graphic/130164.html" rel="external">table 3</a>). (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic hepatitis B virus coinfection, a tenofovir-containing regimen should be used. Regimens that include <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> without tenofovir (eg, <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a>, <a class="drug drug_general" data-topicid="96759" href="/z/d/drug information/96759.html" rel="external">dolutegravir-abacavir-lamivudine</a>) should be avoided, since lamivudine monotherapy for treatment of hepatitis B virus (HBV) has been associated with the rapid emergence of lamivudine-resistant HBV. (See <a class="local">'Hepatitis B virus coinfection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with reduced kidney function, we generally avoid <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF), which is associated with proximal tubular dysfunction. For such patients, the choice of regimen depends on the severity of kidney disease. (See <a class="local">'Reduced kidney function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with moderately reduced kidney function (estimated glomerular filtration rate [eGFR] ≥30 mL/min/1.73 m<sup>2</sup> but &lt;60 mL/min/1.73 m<sup>2</sup>), <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a> or <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a> can be used. <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">Dolutegravir-lamivudine</a> is also an option for many patients, assuming they meet the criteria described below. (See <a class="local">'Moderately reduced kidney function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with severely reduced kidney function (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) who are not on dialysis, we suggest <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For such patients, both <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF) and TDF should be avoided. However, if dolutegravir plus lamivudine cannot be used because the patient does not meet the criteria described below, the approach must be individualized, taking into account the presence of other comorbid conditions. (See <a class="local">'Severely reduced kidney function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> is being considered, it can <strong>only</strong> be used for patients who meet all of the following criteria: HIV viral load &lt;500,000 copies/mL, no evidence of chronic HBV, no transmitted nucleoside reverse transcriptase inhibitor (NRTI) or integrase strand transfer inhibitor (INSTI) resistance (if INSTI resistance testing was obtained as part of the initial evaluation), and no drug interactions that significantly lower the level of either agent. This regimen should ideally be used in patients with a CD4 count &gt;200 cells/microL, but a low CD4 count is not a contraindication. (See <a class="local">'Considerations when using dolutegravir-lamivudine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have a history of (or are at high risk for) heart disease, any of the preferred regimens can be used  (<a class="graphic graphic_table graphicRef130162" href="/z/d/graphic/130162.html" rel="external">table 2</a>). In such patients we avoid <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>, since available data suggest that abacavir can increase the risk of cardiovascular disease. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with osteoporosis, TDF should be avoided. However, regimens that contain TAF or the regimen <a class="drug drug_general" data-topicid="120975" href="/z/d/drug information/120975.html" rel="external">dolutegravir-lamivudine</a> can be used. (See <a class="local">'Osteoporosis'</a> above and <a class="local">'Considerations when using dolutegravir-lamivudine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HIV who present with opportunistic infections, regimen selection should take into account potential drug interactions. As an example, in patients being treated for active or latent tuberculosis, regimen selection can be affected by the risk of clinically important drug interactions with rifamycins. (See <a class="local">'Patients with opportunistic infections'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">United States Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0 (Accessed on December 18, 2019).</li><li class="breakAll">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. doi:10.1001/jama.2020.17025 (Accessed on October 15, 2020).</li><li class="breakAll">Eron JJ, Wilkin A, Ramgopal M, et al. A daily single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults living with HIV and end stage renal disese on chronic hemodialysis. Presented at IDweek 2020. https://www.natap.org/2020/IDWeek/IDWeek_40.htm.</li><li><a class="nounderline abstract_t">Eron JJ Jr, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV 2018.</a></li><li><a class="nounderline abstract_t">Michienzi SM, Schriever CA, Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS 2019; 30:181.</a></li><li><a class="nounderline abstract_t">Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384:1942.</a></li><li><a class="nounderline abstract_t">Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191.</a></li><li><a class="nounderline abstract_t">Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230.</a></li><li><a class="nounderline abstract_t">Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.</a></li><li><a class="nounderline abstract_t">D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.</a></li><li><a class="nounderline abstract_t">Marcus JL, Neugebauer RS, Leyden WA, et al. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defic Syndr 2016; 71:413.</a></li><li><a class="nounderline abstract_t">Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016; 3:e158.</a></li><li><a class="nounderline abstract_t">Wohl D, Oka S, Clumeck N, et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr 2016; 72:58.</a></li><li class="breakAll">Ryom L, Lundgren JD, El-Sadr WM, et al. Association between cardiovascular disease &amp; contemporarily used protease inhibitors. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA [Abstract 128LB].</li><li><a class="nounderline abstract_t">LaFleur J, Bress AP, Rosenblatt L, et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS 2017; 31:2095.</a></li><li><a class="nounderline abstract_t">Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015; 29:1775.</a></li><li><a class="nounderline abstract_t">Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.</a></li><li class="breakAll">Cerrone M. Rifampin Effect on Tenofovir Alafenamide (TAF) Plasma/Intracellular Pharmacokinetics. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, MA, March 2018.</li><li><a class="nounderline abstract_t">Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393:143.</a></li></ol></div><div id="topicVersionRevision">Topic 129782 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : United States Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0 (Accessed on December 18, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. doi:10.1001/jama.2020.17025 (Accessed on October 15, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.natap.org/2020/IDWeek/IDWeek_40.htm" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Eron JJ, Wilkin A, Ramgopal M, et al. A daily single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults living with HIV and end stage renal disese on chronic hemodialysis. Presented at IDweek 2020. https://www.natap.org/2020/IDWeek/IDWeek_40.htm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30555051" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30381029" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25103176" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917892" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952143" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753925" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387667" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26536316" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036991" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26829661" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26829661" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692532" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372383" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890673" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890673" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30420123" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
